Innova Biosciences Introduces Lightning-Link Rapid Bioconjugation Kits
![](/46/pdcnewsitem/03/38/33/5ezdHe3muaSRZ43.jpg)
Innova Biosciences, a specialist provider of bioconjugation products and services, has launched new antibody and protein labelling kits within its Lightning-Link Rapid range. These kits enable researchers to label primary antibodies or other proteins in just 20 minutes.
Dyes recently launched within this range include high sensitivity Atto dyes and Cy dyes. Innova has also released a rapid biotin conjugation kit which allows for extremely quick protein biotinylation. Despite the short incubation time, the conjugation reaction is sufficient to achieve conjugates with performance characteristics identical to, or better than, those prepared with laborious multistep conjugation procedures.
Lightning-Link is an innovative technology that enables direct labelling of antibodies, proteins, peptides or other biomolecules for use in R&D applications, drug discovery and the development of diagnostic kits. The procedure is easy to use, involves only 30 seconds of hands-on time, and no spin or separation steps are required. In addition, by circumventing the desalting or dialysis steps that commonly interrupt traditional protein labelling procedures, Lightning-Link Rapid technology can be used to label small quantities of antibody with 100% recovery.
Dr Nick Gee, CEO at Innova, said: "The launch of the Lightning-Link kits completes the development of our Rapid conjugation range, and follows on from the success of the original kits, which had a much longer reaction time. This latest product introduction underlines Lightning-Link as one of the world’s leading bioconjugation technologies, offering easy-to-use labelling that provides excellent results with minimal hands on time and 100% yield.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance